AEGiS-PRn: The Female Health Company Receives USAID | DELIVER PROJECT Order for 8.1 Million Units PRNewswireImportant note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Click here to return to PRNewswire main menu
DonateNow
Print this article

The Female Health Company Receives USAID | DELIVER PROJECT Order for 8.1 Million Units

PRNewswire - December 22, 2008


CHICAGO, Dec. 22 /PRNewswire-FirstCall/ -- The Female Health Company (NYSE Alternext: FHC) announced it has received an order for the delivery of 8.1 million female condoms (FC) from John Snow, Inc., which implements the USAID | DELIVER PROJECT, a U.S. Agency for International Development (USAID)- funded project, working to increase the availability of essential health supplies to clients and customers around the world.

For many years, USAID has been among the largest international donors of contraceptives and condoms. The Agency developed an operational plan for its HIV/AIDS "expanded response" strategy which includes the establishment of the Commodity Fund (CF) to centrally-finance male and female condoms for HIV/AIDS programs and to ensure their expedited delivery to countries. Through the Commodity Fund and the President's Emergency Plan for AIDS Relief (PEPFAR), USAID provides male and female condoms to Missions for HIV/AIDS prevention activities.

O. B. Parrish, Chairman and CEO of FHC, praised USAID actions stating, "In continuing female condom procurement, USAID is demonstrating its commitment to supporting HIV/AIDS prevention efforts around the World. This commitment is particularly critical as the Global Community recognizes the increasing numbers of females affected by AIDS." UNAIDS reports that worldwide, 33.2 million people, 15.4 million of which are women aged 15 years and older are now living with HIV. The Global Coalition on Women and AIDS, a UNAIDS Initiative, is calling for more money in AIDS programs that work for women including closing the funding gap for the female condom and microbicides development."

About The Female Health Company, Inc.

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC Female Condom(R), which is primarily distributed by public health organizations and donor groups in over 90 developing countries around the world. World-wide, the Female Condom is available in various programs in 108 countries. The Company owns certain worldwide rights to the FC Female Condom(R), including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, the European Patent Convention, the People's Republic of China, Canada, South Korea and Australia. FC Female Condom(R) is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy.

For more information about the Female Health Company, visit the Company's web site at http://www.femalehealth.com/ or http://www.femalecondom.org/.

"Safe Harbor" statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company's current plan and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communication and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

Source: The Female Health Company, Inc.

CONTACT: Investors, William R. Gargiulo, Jr., +1-231-526-1244, or Donna Felch, +1-312-595-9742, both of The Female Health Company, Inc.

Web site: http://www.femalehealth.com/


081222
PR081233


Copyright © 2008 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019  http://www.prnewswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .